Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
Condition: Endometrial Cancer
Sponsor: Pfizer
Full Title
Protocol C6461018: An Interventional Phase 3, Open Label, Randomized Study to Evaluate Efficacy and Safety of PF-08634404 in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent Mismatch Repair Proficient Endometrial Cancer
Study Treatment
PD-1xVEGF bispecific antibody PF-08634404 in combination with chemotherapy vs pembrolizumab in combination with chemotherapy.
Eligibility/Info
Eligible patients must have an MMR proficient advanced or recurrent endometrial cancer eligible for first line systemic therapy.
Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"
Locations
Babylon Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology
Need More Information?
Our team is here to help answer your questions and guide you through your options.